Zevra Therapeutics Inc.
ZVRA | NASDAQ
$11.67
+$0.06 (+0.52%)
At close: Sep 21, 2026, 4:00 PM ET
$11.44
-$0.23 (-1.97%)
Pre-market:
Sep 22, 2026, 8:56 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 106.47M | 23.61M | 27.46M | 10.16M | 28.65M | 13.29M |
Cost of Revenue | 16.48M | 7.42M | 2.95M | 222K | 2.06M | 1.31M |
Gross Profit | 89.99M | 16.2M | 24.52M | 9.94M | 26.59M | 11.98M |
Operating Income | -4.23M | -87M | -49.6M | -42.57M | 7.73M | -5.61M |
Interest Income | 6.95M | 2.18M | 4.54M | 1.51M | 261K | 89K |
Pretax Income | 86.68M | -90.14M | -46.05M | -26.81M | -8.52M | -12.79M |
Net Income | 83.23M | -105.51M | -46.05M | -26.77M | -8.56M | -12.76M |
Selling & General & Admin | 77.62M | 54.87M | 35.09M | 15.04M | 8.7M | 7.92M |
Research & Development | 12.74M | 42.1M | 39.81M | 19.8M | 10.16M | 8.84M |
Other Expenses | 3.86M | 6.24M | -775K | 17.66M | n/a | 828K |
Operating Expenses | 94.22M | 103.2M | 74.12M | 52.5M | 18.86M | 17.59M |
Interest Expense | 7.98M | 7.35M | 1.5M | 335K | 376K | 7.09M |
Selling & Marketing Expenses | n/a | n/a | n/a | -305K | n/a | n/a |
Cost & Expenses | 110.7M | 110.62M | 77.07M | 52.73M | 20.92M | 18.9M |
Income Tax Expense | 3.45M | 15.37M | n/a | -33K | 34K | -34K |
Shares Outstanding (Basic) | 55.31M | 46.25M | 35.45M | 34.49M | 29.77M | 3.98M |
Shares Outstanding (Diluted) | 57.26M | 46.25M | 35.45M | 34.49M | 29.77M | 3.98M |
EPS (Basic) | 1.40 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 |
EPS (Diluted) | 1.35 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 |
EBITDA | 98.71M | -76.4M | -43.54M | -25.53M | -7.89M | -5.43M |
EBIT | 94.66M | -82.79M | -44.55M | -26.47M | -8.15M | -5.7M |
Depreciation & Amortization | 4.05M | 6.39M | 1.01M | 944K | 257K | 273K |
Add to Watchlist
Select watchlists to add or remove ZVRA